Inactive Instrument

News LYSOGENE

Stocks

LYS

FR0013233475

Biotechnology & Medical Research

All News

23-07-06	Lysogene S.A.(ENXTPA:LYS) dropped from CAC AllShares Index	CI
23-07-06	Lysogene S.A.(ENXTPA:LYS) dropped from Next Biotech Index	CI
23-05-29	Lysogene: placed in liquidation and delisted
23-05-29	Lysogene to Delist from Euronext amid Judicial Liquidation	MT
23-04-29	LYSOGENE : Inside Information / News release on accounts, results	PU
23-04-29	Lysogene S.A. Announces Postponement of 2022 Financial Results Release	CI
23-04-17	Lysogene: no takeover bid received for biotech company
23-04-17	Lysogene Fails to Secure Takeover Bid Amid Reorganization	MT
23-03-27	Lysogene: deadline for takeover bids extended
23-02-06	Lysogene: interim CFO confirmed
23-02-06	French Gene Therapy Group Lysogene Makes Ad Interim CFO Permanent	MT
23-02-03	Lysogene Appoints Côme de La Tour du Pin as Chief Financial Officer	CI
23-01-25	Lysogene: company placed in receivership
23-01-09	Lysogene: officially looking for a buyer
22-12-07	Lysogene Seeks Launch of Safeguard Process Amid Financing Woes	MT
22-12-06	LYSOGENE : Inside Information / Operations of the issuer (acquisitions, sales...)	PU
22-11-29	Lysogene : Announces Favorable DSMB Review Recommending Study Continuation and Positive Biomarker Data in Stage 1 of Adaptative Clinical Trial with LYS-GM101 Gene Therapy in GM1 Gangliosidosis	PU
22-11-21	Lysogene to Provide Updates and Topline Results from Phase 2/3 AAVance Gene Therapy Clinical Study and Host Webcast on Wednesday November 23, 2022	AQ
22-11-18	Lysogene Provides Updates and Topline Results from Phase 2/3 Aavance Gene Therapy Clinical Study	CI
22-11-18	LYSOGENE : Inside Information / Other news releases	PU
22-09-23	Lysogene S.A. Reports Earnings Results for the Half Year Ended June 30, 2022	CI
22-09-16	Lysogene Announces New Board of Directors	CI
22-07-11	LYSOGENE : Half-year liquidity contract statement for LYSOGENE	PU
22-07-07	Lysogene's Gene Therapy Improves Cognitive, Motor Functions In Initial Phase 2/3 Data	MT
22-07-07	Lysogene : Provides Additional Update on AAVance Phase 2/3 Gene Therapy Clinical Trial with LYS-SAF302 in children with MPS IIIA	PU